Adherence to mepolizumab
| Descriptive statistics | |
| Proportion of days covered (PDC, (mean)) | 0.7 |
| PDC (median) | 0.8 |
| No/per cent patients by PDC category | % (n) |
| PDC≥25% | 91 (1643) |
| PDC≥50% | 77 (1377) |
| PDC≥75% | 62 (1107) |
| PDC=100% | 2 (38) |
| No/per cent patients | % n |
| Early-stage persistence | 65 (1176) |
| Discontinuation by catgeory | % (n) |
| No refill within 3 months | 11 (202) |
| No refill within 6 months | 7 (120) |
| No refill within 9 months | 6 (106) |
| No refill within 12 months | 6 (99) |
| Time to discontinuation | No of days |
| Mean | 68 |
| Median | 28 |
| With 28-day allowable gap (mean) | 233 |
| With 28-day allowable gap (median) | 271 |
N=1801.